Efficacy and Safety of An'Ningpai Expectorant in Non-CF Bronchiectasis
Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
The objective of this study was to assess whether the long-term use of oral An'Ningpai
Enteric Soft Capsuleson (300 mg, three times daily, 12 months) might reduce the incidence of
exacerbations and improve the quality of life in patients with Non-CF bronchiectasis.